R&D Views & Analysis | pharmaphorum

Monday 13 July 2026

Views & Analysis

R&D

Hexagonal rendering of AI concept on dark blue background

Results, reality, and recalibration: Unpacking AI hype at SC...

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

R&D

life sciences investment projections

Why the government’s latest funding push is critical to the ...

Many of the UK’s most promising life sciences innovations continue to face persistent funding challenges, made worse by an increasingly volatile globa

R&D

Representation of a complex molecule

Navigating development in a complex molecule world

For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly.

R&D

Board meeting, sunset behind speaker

Changing Faces: Board of Directors, January 2026

January was a relatively quiet month for Board news, but there were some notable moves here and there.

R&D

JPM2026 wrap-up with Nicole Raleigh and Jonah Comstock

On JPM2026 and healthcare investment today, with Jonah Comst...

Editor-in-chief Jonah Comstock sat down with pharmaphorum web editor Nicole Raleigh to discuss JPM2026.

R&D

Representation of bipolar and other mental health disorders, Janus concept

The role of the opioid pathway in schizophrenia and bipolar ...

Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.